Published in J Clin Psychiatry on August 01, 1999
History of the development of sleep medicine in the United States. J Clin Sleep Med (2005) 4.22
Efficacy and safety of 6-month nightly ramelteon administration in adults with chronic primary insomnia. Sleep (2009) 2.89
Evaluation of the efficacy and safety of ramelteon in subjects with chronic insomnia. J Clin Sleep Med (2007) 1.17
Clinical Practice Guideline for the Pharmacologic Treatment of Chronic Insomnia in Adults: An American Academy of Sleep Medicine Clinical Practice Guideline. J Clin Sleep Med (2017) 1.17
Efficacy, safety and cost of new drugs acting on the central nervous system. Eur J Clin Pharmacol (2003) 1.11
Sleep in the Elderly: Burden, Diagnosis, and Treatment. Prim Care Companion J Clin Psychiatry (2004) 1.01
Meta-analyses of hypnotics and infections: eszopiclone, ramelteon, zaleplon, and zolpidem. J Clin Sleep Med (2009) 0.99
Efficacy and Safety of Doxepin 1 mg and 3 mg in a 12-week Sleep Laboratory and Outpatient Trial of Elderly Subjects with Chronic Primary Insomnia. Sleep (2010) 0.97
Is the increasing use of evidence-based pharmacotherapy causing the renaissance of complementary medicine? Br J Clin Pharmacol (2003) 0.97
Update on the safety considerations in the management of insomnia with hypnotics: incorporating modified-release formulations into primary care. Prim Care Companion J Clin Psychiatry (2007) 0.96
The societal costs of insomnia. Neuropsychiatr Dis Treat (2010) 0.94
Noise-induced sleep maintenance insomnia: hypnotic and residual effects of zaleplon. Br J Clin Pharmacol (2002) 0.85
A visual ERP study of impulse inhibition following a zaleplon-induced nap after sleep deprivation. PLoS One (2014) 0.77
The Importance of Residual Effects When Choosing a Hypnotic: The Unique Profile of Zaleplon. Prim Care Companion J Clin Psychiatry (2001) 0.76
An approach to long-term sedative-hypnotic use. Nat Sci Sleep (2012) 0.75
The effects of music relaxation and muscle relaxation techniques on sleep quality and emotional measures among individuals with posttraumatic stress disorder. Ment Illn (2012) 0.75
Dipyrazolo[1,5-a:4',3'-c]pyridines - a new heterocyclic system accessed via multicomponent reaction. Beilstein J Org Chem (2012) 0.75
Clinical evaluation of zaleplon in the treatment of insomnia. Nat Sci Sleep (2010) 0.75
Somatosensory discrimination based on cortical microstimulation. Nature (1998) 2.85
Comparison of aerobic exercise, clomipramine, and placebo in the treatment of panic disorder. Am J Psychiatry (1998) 1.86
Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry (2001) 1.81
Touch and go: decision-making mechanisms in somatosensation. Annu Rev Neurosci (2001) 1.80
Severe and uncommon involuntary movement disorders due to psychotropic drugs. Pharmacopsychiatry (2004) 1.63
Discrimination in the sense of flutter: new psychophysical measurements in monkeys. J Neurosci (1997) 1.59
Moderate alcohol consumption in social drinkers raises plasma homocysteine levels: a contradiction to the 'French Paradox'? Alcohol Alcohol (2001) 1.50
The sleep-improving effects of doxepin are paralleled by a normalized plasma cortisol secretion in primary insomnia. A placebo-controlled, double-blind, randomized, cross-over study followed by an open treatment over 3 weeks. Psychopharmacology (Berl) (2003) 1.45
Eosinophilia-myalgia syndrome in Germany: an epidemiologic review. Mayo Clin Proc (1994) 1.44
Changes in heart rate during obstructive sleep apnoea. Eur Respir J (1992) 1.43
Highly conserved and disease-specific patterns of carboxyterminally truncated Abeta peptides 1-37/38/39 in addition to 1-40/42 in Alzheimer's disease and in patients with chronic neuroinflammation. J Neurochem (2002) 1.40
[Recommendations for diagnosis, therapy and long-term management of patients with sleep apnea]. Med Klin (Munich) (1991) 1.40
Improvement of cognitive functions in chronic schizophrenic patients by recombinant human erythropoietin. Mol Psychiatry (2006) 1.38
Improved electrophoretic separation and immunoblotting of beta-amyloid (A beta) peptides 1-40, 1-42, and 1-43. Electrophoresis (1997) 1.37
Blood dyscrasias induced by psychotropic drugs. Pharmacopsychiatry (2004) 1.31
Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA (2000) 1.29
Age-associated changes in the densities of presynaptic monoamine transporters in different regions of the rat brain from early juvenile life to late adulthood. Brain Res Dev Brain Res (2000) 1.26
Doxepin in the treatment of primary insomnia: a placebo-controlled, double-blind, polysomnographic study. J Clin Psychiatry (2001) 1.19
Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Mol Psychiatry (2004) 1.18
Amyloid beta peptides in plasma in early diagnosis of Alzheimer's disease: A multicenter study with multiplexing. Exp Neurol (2009) 1.17
Severe adverse drug reactions of antidepressants: results of the German multicenter drug surveillance program AMSP. Pharmacopsychiatry (2004) 1.16
Sleep apnea syndrome and cerebral hemodynamics. Chest (1996) 1.15
Zaleplon shortens subjective sleep latency and improves subjective sleep quality in elderly patients with insomnia. The Zaleplon Clinical Investigator Study Group. Int J Geriatr Psychiatry (2000) 1.11
Assessment of intracranial hemodynamics in sleep apnea syndrome. Stroke (1992) 1.08
Early methylphenidate administration to young rats causes a persistent reduction in the density of striatal dopamine transporters. J Child Adolesc Psychopharmacol (2001) 1.05
Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias. Mol Psychiatry (2007) 1.05
Adverse drug reactions. An epidemiological study at psychiatric hospitals. Acta Psychiatr Scand (1984) 1.05
Evolution of Abeta42 and Abeta40 levels and Abeta42/Abeta40 ratio in plasma during progression of Alzheimer's disease: a multicenter assessment. J Nutr Health Aging (2009) 1.04
High-frequency repetitive transcranial magnetic stimulation delays rapid eye movement sleep. Neuroreport (1998) 1.00
The AMSP drug safety program: methods and global results. Pharmacopsychiatry (2004) 0.98
Trimipramine in primary insomnia: results of a polysomnographic double-blind controlled study. Pharmacopsychiatry (2002) 0.98
Sensing and deciding in the somatosensory system. Curr Opin Neurobiol (1999) 0.97
Functional properties of primate putamen neurons during the categorization of tactile stimuli. J Neurophysiol (1997) 0.97
Isoform pattern of 14-3-3 proteins in the cerebrospinal fluid of patients with Creutzfeldt-Jakob disease. J Neurochem (1999) 0.97
[Direct and indirect costs of schizophrenia]. Fortschr Neurol Psychiatr (1999) 0.95
Nocturnal plasma melatonin levels in patients suffering from chronic primary insomnia. J Pineal Res (1995) 0.94
Two cases of olanzapine-induced reversible neutropenia. Pharmacopsychiatry (1999) 0.94
Evaluation of oxidative stress measurements in obstructive sleep apnea syndrome. J Neural Transm (Vienna) (2005) 0.94
Effects of chronic treatment with methadone and naltrexone on sleep in addicts. Eur Arch Psychiatry Clin Neurosci (1996) 0.94
The AMUP study for drug surveillance in psychiatry - a summary of inpatient data. Pharmacopsychiatry (2004) 0.93
Elevated homocysteine levels in alcohol withdrawal. Alcohol Alcohol (2000) 0.93
Elevation of beta-amyloid peptide 2-42 in sporadic and familial Alzheimer's disease and its generation in PS1 knockout cells. J Biol Chem (2001) 0.92
Homocysteine induces cell death of rat astrocytes in vitro. Neurosci Lett (2003) 0.92
Nocturnal myoclonus syndrome (periodic movements in sleep) related to central dopamine D2-receptor alteration. Eur Arch Psychiatry Clin Neurosci (1995) 0.91
Tolerability of long term clozapine treatment. Psychopharmacology (Berl) (1989) 0.89
Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry (2001) 0.89
[Follow-up study after enteral manganese poisoning: clinical, laboratory and neuroradiological findings]. Nervenarzt (2000) 0.89
CSF diagnosis of Alzheimer's disease and dementia with Lewy bodies. J Neural Transm (Vienna) (2006) 0.88
Long-term food restriction down-regulates the density of serotonin transporters in the rat frontal cortex. Biol Psychiatry (1997) 0.88
Relationship between cerebral blood flow velocities and cerebral electrical activity in sleep. Sleep (1994) 0.88
Assessment of adverse drug reactions in psychiatric inpatients with the AMSP drug safety program: methods and first results for tricyclic antidepressants and SSRI. Pharmacopsychiatry (1999) 0.87
Nocturnal melatonin secretion and sleep after doxepin administration in chronic primary insomnia. Pharmacopsychiatry (1996) 0.87
Hyperhomocysteinemia as a new risk factor for brain shrinkage in patients with alcoholism. Neurosci Lett (2003) 0.87
Psychotropic drug use in psychiatric inpatients: recent trends and changes over time-data from the AMSP study. Pharmacopsychiatry (2004) 0.86
Acquired transmission-blocking immunity to Plasmodium vivax in a population of southern coastal Mexico. Am J Trop Med Hyg (1996) 0.86
Rebound insomnia after hypnotic withdrawal in insomniac outpatients. Eur Arch Psychiatry Clin Neurosci (1998) 0.86
Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Transm (Vienna) (2000) 0.86
CPAP-therapy effectively lowers serum homocysteine in obstructive sleep apnea syndrome. J Neural Transm (Vienna) (2004) 0.86
Dopamine D2 receptor alteration in patients with periodic movements in sleep (nocturnal myoclonus). J Neural Transm Gen Sect (1993) 0.86
Plasma homocysteine is a predictor of alcohol withdrawal seizures. Neuroreport (2000) 0.86
Evaluating depressive symptoms and their impact on outcome in schizophrenia applying the Calgary Depression Scale. Acta Psychiatr Scand (2010) 0.86
Dependence of a sleeping parameter from the N-S or E-W sleeping direction. Z Naturforsch C (1988) 0.86
Effects of transmission-blocking immunity on Plasmodium vivax infections in Anopheles albimanus populations. J Parasitol (1994) 0.85
Severe adverse drug reactions in psychiatric inpatients treated with neuroleptics. Pharmacopsychiatry (2004) 0.85
A combination of galantamine and memantine modifies cognitive function in subjects with amnestic MCI. J Nutr Health Aging (2012) 0.85
Persistently increased density of serotonin transporters in the frontal cortex of rats treated with fluoxetine during early juvenile life. J Child Adolesc Psychopharmacol (1999) 0.85
Anhedonia and blunted affect in major depressive disorder. Compr Psychiatry (1995) 0.85
Severe tardive dystonia: treatment with continuous intrathecal baclofen administration. Mov Disord (1997) 0.85
Assessment of adverse drug reactions in psychiatric hospitals. Eur J Clin Pharmacol (1984) 0.85
Anti-syntaxin antibodies inhibit calcium-dependent catecholamine secretion from permeabilized chromaffin cells. Biochem Biophys Res Commun (1995) 0.84
Pisa syndrome (pleurothotonus): report of a multicenter drug safety surveillance project. J Clin Psychiatry (2000) 0.84
Physical anhedonia in major depressive disorder. J Affect Disord (1992) 0.84
Comparison of psychotropic drug intake in two populations in West Germany. Results from the Munich Blood Pressure Study 1980/81 and the Luebeck Blood Pressure Study 1984. Pharmacopsychiatry (1987) 0.84
Escherichia coli in settled-dust and air samples collected in residential environments in Mexico City. Appl Environ Microbiol (1997) 0.84
Effects of beta-receptor blockers in pharmacology EEG. Neuropsychobiology (1983) 0.84
Flupentixol use and adverse reactions in comparison with other common first- and second-generation antipsychotics: data from the AMSP study. Eur Arch Psychiatry Clin Neurosci (2013) 0.84
[Neuronal potassium channel opening with flupirtine]. Fortschr Neurol Psychiatr (1999) 0.83
Effects of the beta-adrenoceptor blocking agent sotalol on CNS: sleep, EEG, and psychophysiological parameters. J Clin Pharmacol (1979) 0.83
Role of primary somatic sensory cortex in the categorization of tactile stimuli: effects of lesions. Exp Brain Res (1997) 0.83
Cerebrovascular reactivity to acetazolamide in (senile) dementia of Alzheimer's type: relationship to disease severity. Dementia (1995) 0.83
Causes and consequences of the loss of serotonergic presynapses elicited by the consumption of 3,4-methylenedioxymethamphetamine (MDMA, "ecstasy") and its congeners. J Neural Transm (Vienna) (1997) 0.82
Chronic manganism: fourteen years of follow-up. J Neuropsychiatry Clin Neurosci (1999) 0.82
Agranulocytosis and significant leucopenia with neuroleptic drugs: results from the AMUP program. Psychopharmacology (Berl) (1989) 0.82
Decreased sleep quality and increased sleep related movements in patients with Tourette's syndrome. J Neurol Neurosurg Psychiatry (2001) 0.82
Olanzapine treatment of obsessive-compulsive disorder. Can J Psychiatry (2000) 0.82
[Value of sports in treatment of psychiatric illness]. Psychother Psychosom Med Psychol (1997) 0.82
Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry (1984) 0.82
Insight in schizophrenia-course and predictors during the acute treatment phase of patients suffering from a schizophrenia spectrum disorder. Eur Psychiatry (2012) 0.82
Pattern of symptom improvement following treatment with venlafaxine XR in patients with generalized anxiety disorder. J Clin Psychiatry (2001) 0.82
Myocarditis associated with clozapine treatment. Aust N Z J Psychiatry (2000) 0.82
Decreased neuroendocrine responses to meta-chlorophenylpiperazine (m-CPP) but normal responses to ipsapirone in marathon runners. Neuropsychopharmacology (1999) 0.81
Serotonin transporters in the rat frontal cortex: lack of circadian rhythmicity but down-regulation by food restriction. J Neurochem (1996) 0.81
The prediction of acute response, remission and general outcome of neuroleptic treatment in acute schizophrenic patients. Pharmacopsychiatria (1983) 0.81
Altered circadian melatonin secretion patterns in relation to sleep in patients with chronic sleep-wake rhythm disorders. J Pineal Res (1998) 0.81
Lithium decreases secretion of Abeta1-42 and C-truncated species Abeta1-37/38/39/40 in chicken telencephalic cultures but specifically increases intracellular Abeta1-38. Neurodegener Dis (2004) 0.81
Elevated serum levels of astroglial S100beta in patients with liver cirrhosis indicate early and subclinical portal-systemic encephalopathy. Metab Brain Dis (1999) 0.81
Pergolide: treatment of choice in Restless Legs Syndrome (RLS) and Nocturnal Myoclonus Syndrome (NMS). Longterm follow up on pergolide. Short communication. J Neural Transm (Vienna) (1998) 0.81